Home » Stocks » Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC (ADAP)

Stock Price: $7.86 USD -0.05 (-0.63%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $7.85 -0.01 (-0.13%) Aug 13, 5:29 PM

Stock Price Chart

Key Info

Market Cap 1.22B
Revenue (ttm) 2.23M
Net Income (ttm) -126.71M
Shares Out 154.61M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $7.86
Previous Close $7.91
Change ($) -0.05
Change (%) -0.63%
Day's Open 7.89
Day's Range 7.62 - 7.96
Day's Volume 373,963
52-Week Range 0.71 - 13.40

More Stats

Market Cap 1.22B
Enterprise Value 815.24M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 154.61M
Float 83.57M
EPS (basic) -1.14
EPS (diluted) -1.08
FCF / Share -0.37
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.72M
Short Ratio 4.60
Short % of Float n/a
Beta 2.33
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 545.44
PB Ratio 3.08
Revenue 2.23M
Operating Income -130.49M
Net Income -126.71M
Free Cash Flow -51.04M
Net Cash 400.01M
Net Cash / Share 2.59
Gross Margin -4,325.81%
Operating Margin -5,856.96%
Profit Margin -5,687.30%
FCF Margin -2,291.02%
ROA -21.70%
ROE -42.62%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 4
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$12.67*
(61.20% upside)
Low
9.00
Current: $7.86
High
17.00
Target: 12.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue1.1259.5137.8314.209.870.83
Revenue Growth-98.11%57.28%166.47%43.84%1096.48%-
Gross Profit1.1259.5137.8314.209.870.83
Operating Income-140-82.37-80.66-72.80-24.64-11.52
Net Income-137-95.51-70.14-71.58-22.06-11.60
Shares Outstanding630584528425215148
Earnings Per Share-1.32-0.96-0.78-1.02-1.02-0.48
Operating Cash Flow-113-104-54.32-48.17-29.6736.84
Capital Expenditures-1.59-3.91-24.09-11.51-4.96-1.37
Free Cash Flow-114-108-78.41-59.67-34.6235.47
Cash & Equivalents94.042092131852840.00
Total Debt25.46-----
Net Cash / Debt68.582092131852840.00
Assets182277281235301-
Liabilities57.9129.8578.1668.3741.65-
Book Value124247203166259-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adaptimmune Therapeutics PLC
Country United Kingdom
Employees 383
CEO Adrian Rawcliffe

Stock Information

Ticker Symbol ADAP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADAP
IPO Date May 6, 2015

Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.